PBS Growth Hormone Program (Paediatric Use) 1 February 2019 Listing Changes

Page last updated: 1 February 2019

[Note, this News item is no current and the links have been removed]

Changes to the Pharmaceutical Benefits Scheme (PBS) restrictions for growth hormone (GH) treatment (paediatric use), which set out the eligibility requirements for PBS subsidy, are being introduced on 1 February 2019.

These changes broaden the eligibility criteria for access to PBS-subsidised GH for paediatric patients in specific clinical circumstances.  They relate to height percentile and growth velocity eligibility thresholds, growth velocity measurement intervals and associated growth data requirements. Specification of relevant criteria within the PBS restrictions has also been streamlined.

A detailed summary of the changes is available on the PBS website.